Navigation Links
American Orthopedic Spine Surgeon Successfully Treated for Autoimmune Arthritis with His Own Stem Cells
Date:1/26/2011

GERMANTOWN, Md., Jan. 26, 2011 /PRNewswire/ -- RNL BIO CO., LTD, a leading biopharmaceutical company specialized in adult stem cell therapeutics, announced on January 21, 2011 another successful patient report utilizing stem cell therapy on a leading US orthopedic spine surgeon who suffered from Autoimmune Arthritis.  

Dr. Stanley Jones, the surgeon and patient, reports that he had a sudden onset of acute pain in his wrist in September 2009; shortly thereafter the patient experiences pain in his knees as well.  Dr. Jones saw a rheumatologist who diagnosed him with Autoimmune Arthritis.  He was placed on Cortisone, a steroid hormone, to suppress immune response and alleviate pain.  Unfortunately Dr. Jones suffered complications from the Cortisone including chest pain and Candidiasis which were unbearable.  His condition deteriorated and his ability to perform routine activities of daily living or his profession was impacted.  

After visiting many physicians and talking with experts in the field, Dr. Jones was introduced to RNL Bio's stem cell therapy.  After a workup, he received stem cell infusions in Kyoto, Japan in May 2010.  Post infusion, he began to notice improvement and by the 5 month, he had a complete recovery and was able to resume sports as well as operating!  In addition, he no longer needed any medications including Cortisone or Methotrexate.  Dr. Jones' rheumatologist in Houston saw Dr. Jones post infusion and said, "It is amazing that Dr. Jones was able to experience improvement from cutting-edge medical technology."

Other patients treated by the company have had very successful results as reported by RNL BIO Co., Ltd in 2009, an American artist, John Cullison's stem cell treatment for Rheumatoid Arthritis, and in September 2010, Japanese Yosida's treatment for psoriasis.

About RNL BIO CO., LTD.

RNL BIO is a premier biotechnology company focused on the research and development of adult derived stem cell therapies.  RNL has two therapies in Phase II clinical trials for Buerger's Disease as well as Osteoarthritis and one phase I trial for spinal cord injury.  RNL is a publicly traded company on the Korean Stock Exchange (Code 003190) and is expanding its operations throughout the world.

Video Interview Link:

http://www.youtube.com/watch?v=xzDElPr9gRo

Related Link:

http://www.rnl.co.kr/eng/main.asp


'/>"/>
SOURCE RNL BIO CO., LTD.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Oriental Bioengineerings CEO and CFO Visit the United States as Entrepreneur Representatives of President Hu Jintaos Delegation
2. Maldonado Medicals Green Initiative, a Model for the American Small Business
3. American Medical Systems Launches STEP Patient Education Program in Europe
4. American Scientific Resources, Inc. Announces S-1 Registration Statement Effective; Commences Public Reporting Requirements
5. Amarin Announces Successful Completion of Offering of American Depositary Shares
6. Amarin Prices Public Offering of American Depositary Shares
7. Pharmacists Encourage Americans to Consider Medicine Cabinet Cleanout Among New Years Resolutions
8. CVS CAREMARK to Purchase Universal Americans Medicare Part D Business
9. American Regent Initiates Nationwide Voluntary Recall of Sodium Bicarbonate Injection, USP 7.5% and 8.4%, 50 mL Single Dose Vials Due to Particulate Matter
10. Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences
11. Red Cross Supports Pan American Health Organization with $1.5 Million in Medicine and Supplies for Cholera Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Inc. (NASDAQ: IPXL ) today announced that it plans to ... Raymond James and Associates, 38 th Annual Institutional Investors Conference ... FL. Cowen and Company 37 th ... in Boston, MA. Barclays Global ... Miami, FL. Individuals may listen to ...
(Date:2/27/2017)... Leading Countries, Technologies and Companies The global ... CAGR of 8.9% from 2016-2021 and CAGR of 9.2% from 2021-2027. ... from 2016 to 2027. The market is estimated at $816m in ... ... to discover how you can exploit the future business opportunities emerging ...
(Date:2/27/2017)... 27, 2017 Period October – December 2016 ... result amounted to SEK -16.4 (-6.4) million Result after tax ... before and after dilution Cash flow from operating activities amounted ... ... (0.4) million Operating result amounted to SEK -39.5 (-29.5) million ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... ... staffing, scheduling, and reporting for healthcare organizations. This comprehensive and customizable solution ... staffing process. StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects critical ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ... Parkinson’s disease (PD) in persons with a specific LRRK2 mutation, according to a ... , Previous studies have provided evidence of a link between pesticides and incidence ...
(Date:2/24/2017)... ... February 24, 2017 , ... Houston dentist , ... office, Antoine Dental Center. Currently, patients can get single dental implants for $3,599 ... patients can learn more about these offers by contacting Antoine Dental Center. Both ...
(Date:2/24/2017)... ... ... An in-depth computational analysis of genetic variants implicated in both schizophrenia and rheumatoid ... explain why susceptibility to one of the disorders could place individuals at lower risk ... journal npj Schizophrenia. , “There is a wealth of genomic data on both ...
(Date:2/24/2017)... ... 24, 2017 , ... In the Health Care IT campaign, Robert Herjavec discusses ... not if you will be attacked, but when.” However, he and many others involved ... care. , Improvements in auditing and monitoring have taken security in health care a ...
Breaking Medicine News(10 mins):